- Report
- September 2023
- 227 Pages
China
From €3876EUR$4,000USD£3,320GBP
- Report
- July 2023
- 119 Pages
Global
From €3500EUR$3,869USD£3,103GBP
- Report
- April 2022
- 81 Pages
Global
From €3500EUR$3,869USD£3,103GBP
- Report
- April 2023
- 107 Pages
Global
From €3500EUR$3,869USD£3,103GBP
- Report
- July 2021
- 78 Pages
Global
From €3200EUR$3,537USD£2,837GBP
- Report
- September 2022
- 359 Pages
Global
From €2423EUR$2,500USD£2,075GBP
- Report
- May 2022
- 51 Pages
Global
From €1938EUR$2,000USD£1,660GBP
- Report
- September 2023
- 109 Pages
China
From €1744EUR$1,800USD£1,494GBP
- Report
- March 2023
- 132 Pages
Global
From €921EUR$950USD£789GBP
- Report
- March 2023
- 322 Pages
Global
From €5553EUR$5,730USD£4,756GBP
- Report
- January 2021
- 130 Pages
Global
From €5978EUR$6,168USD£5,120GBP
- Report
- April 2023
- 160 Pages
Global
From €5814EUR$5,999USD£4,979GBP
- Report
- February 2024
- 180 Pages
Global
From €5329EUR$5,499USD£4,564GBP
The Tuberculosis Drug market is a subset of the larger Respiratory Drug market. It is composed of drugs used to treat tuberculosis, a bacterial infection that affects the lungs and other parts of the body. These drugs are typically antibiotics, such as isoniazid, rifampicin, and ethambutol, and are used in combination to treat the infection. The drugs are usually taken for a period of six to nine months, and are often used in combination with other treatments, such as surgery or chemotherapy.
The Tuberculosis Drug market is highly competitive, with many companies offering different combinations of drugs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Sanofi, Merck, and Novartis. Other companies, such as Cipla, Lupin, and Sun Pharmaceuticals, also offer a range of tuberculosis drugs. Show Less Read more
